| Bioactivity | U18666A, an intra-cellular cholesterol transport inhibitor, inhibits replication of Ebola virus, dengue virus, and human hepatitis C virus[1]. |
| Target | Cholesterol. |
| Invitro | U18666A, the antiviral effect is found to result from two events: retarded viral trafficking in the cholesterol-loaded late endosomes/lysosomes and suppresse de novo sterol biosynthesis in treated infected cells. It is also observed an additive antiviral effect of U18666A with C75, a fatty acid synthase inhibitor, suggesting dengue virus relies on both the host cholesterol and fatty acid biosynthesis for successful replication[1][2]. |
| Name | U18666A |
| CAS | 3039-71-2 |
| Formula | C25H42ClNO2 |
| Molar Mass | 424.06 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
| Reference | [1]. Poh MK, et al. U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication. Antiviral Res. 2012 Jan;93(1):191-8. [2]. Cenedella RJ, et al. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids. 2009 Jun;44(6):477-87. |